• DOI:10.1007/s10637-016-0422-z
Corpus ID: 596267

A first-in-human Phase 1 study of epirubicin-conjugated polymer micelles (K-912/NC-6300) in patients with advanced or recurrent solid tumors

@article{Mukai2016AFP,
  title={A first-in-human Phase 1 study of epirubicin-conjugated polymer micelles (K-912/NC-6300) in patients with advanced or recurrent solid tumors},
  author={H. Mukai and T. Kogawa and N. Matsubara and Y. Naito and M. Sasaki and A. Hosono},
  journal={Investigational New Drugs},
  year={2016},
  volume={35},
  pages={307-314}
}

• H. Mukai, T. Kogawa, +3 authors A. Hosono
• Published 2016
• Medicine
• Investigational New Drugs

SummaryBackground K-912 also known as NC-6300 is a novel epirubicin pro-drug conjugate developed using micellar nanoparticle technology. We conducted a first-in-human, Phase 1, open-label, non-randomized dose escalation study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of K-912 administered as monotherapy in patients with advanced or recurrent solid tumors. Methods Patients aged 41 to 72 years with histologically or cytologically confirmed advanced or recurrent… Expand